Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13293667 | 0.76 | SMN1; SMN2 (0.54) | CYP2A6OPRM1OPRK1ROCK2MCHR1 | |
| SCHEMBL2962869 | 0.73 | CYP2A6 (0.53) | CYP2A6SIGMAR1ROCK2HCRTR1HCRTR2 | |
| SCHEMBL3144878 | 0.72 | CYP2A6 (0.59) | CYP2A6SIGMAR1HCRTR1HCRTR2MRGPRX4 | |
| SCHEMBL5547137 | 0.68 | CYP2A6 (0.54) | CYP2A6SIGMAR1HCRTR1HCRTR2MRGPRX4 | |
| SCHEMBL11517673 | 0.68 | CYP2A6 (0.50) | CYP2A6SIGMAR1ROCK2MCHR1 | |
| SCHEMBL3480315 | 0.68 | CA2 (0.54) | CYP2A6MCHR1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL30128338 | 0.68 | LTA4H (0.56) | SIGMAR1SLC6A3 | |
| SCHEMBL22415759 | 0.67 | SIGMAR1 (0.51) | CYP2A6SIGMAR1OPRM1OPRK1ROCK2 | |
| SCHEMBL10368304 | 0.67 | SIGMAR1 (0.51) | CYP2A6SIGMAR1MRGPRX4PDE10ASLC6A4 | |
| SCHEMBL2091182 | 0.66 | CYP2A6 (0.61) | CYP2A6SIGMAR1OPRM1OPRK1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10039744-B2 | Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2018-08-07 | — | — | US | disclosed |
| US-20180153855-A1 | SIGMA RECEPTOR-BINDING AGENT | TOYAMA CHEMICAL CO., LTD. (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20170165227-A1 | POST NERVE INJURY REHABILITATION EFFECT-ENHANCING AGENT COMPRISING ALKYL ETHER DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2017-06-15 | — | — | US | disclosed |
| US-8173633-B2 | Protein kinase C activity enhancer containing alkyl ether derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8119625-B2 | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20110245228-A1 | PROTEIN KINASE C ACTIVITY ENHANCER CONTAINING ALKYL ETHER DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-10-06 | — | — | US | disclosed |
| US-8026232-B2 | Benzothiophene oxide derivative and salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20110077413-A1 | NOVEL BENZOTHIOPHENE OXIDE DERIVATIVE AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20100184997-A1 | PROTEIN KINASE C ACTIVITY ENHANCER CONTAINING ALKYL ETHER DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-22 | — | — | US | disclosed |
| US-20090209512-A1 | NEUROGENESIS INDUCER OR NEUROPATHY THERAPEUTIC AGENT COMPRISING ALKYL ETHER DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090093453-A1 | NEUROGENESIS INDUCER OR NEUROPATHY THERAPEUTIC AGENT COMPRISING ALKYL ETHER DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD (JP) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184997-A1 | PROTEIN KINASE C ACTIVITY ENHANCER CONTAINING ALKYL ETHER DERIVATIVE OR SALT THEREOF | PRKCH, PRKCA, PRKCB | CYP2A6 4551/4885SIGMAR1 3434/4885OPRM1 3599/4885 |
| US-10039744-B2 | Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof | NGF, BDNF, NTRK2 | CYP2A6 4147/4885SIGMAR1 782/4885OPRM1 1091/4885 |
| US-20180153855-A1 | SIGMA RECEPTOR-BINDING AGENT | SIGMAR1, OPRM1, TMEM97 | CYP2A6 418/4885SIGMAR1 1/4885OPRM1 2/4885 |
| US-20090093453-A1 | NEUROGENESIS INDUCER OR NEUROPATHY THERAPEUTIC AGENT COMPRISING ALKYL ETHER DERIVATIVE OR SALT THEREOF | NGF, GAP43, BDNF | CYP2A6 3976/4885SIGMAR1 2156/4885OPRM1 1130/4885 |
| US-20170165227-A1 | POST NERVE INJURY REHABILITATION EFFECT-ENHANCING AGENT COMPRISING ALKYL ETHER DERIVATIVE OR SALT THEREOF | NGF, BDNF, NTRK2 | CYP2A6 4147/4885SIGMAR1 782/4885OPRM1 1091/4885 |
| US-20090209512-A1 | NEUROGENESIS INDUCER OR NEUROPATHY THERAPEUTIC AGENT COMPRISING ALKYL ETHER DERIVATIVE OR SALT THEREOF | NGF, GAP43, BDNF | CYP2A6 3976/4885SIGMAR1 2156/4885OPRM1 1130/4885 |
| US-20110245228-A1 | PROTEIN KINASE C ACTIVITY ENHANCER CONTAINING ALKYL ETHER DERIVATIVE OR SALT THEREOF | PRKCH, PRKCA, PRKCB | CYP2A6 4551/4885SIGMAR1 3434/4885OPRM1 3599/4885 |
| US-20110077413-A1 | NOVEL BENZOTHIOPHENE OXIDE DERIVATIVE AND SALT THEREOF | TH, EBPL, IL4I1 | CYP2A6 532/4885SIGMAR1 1057/4885OPRM1 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.